Overview Dividends

(ALHC) Alignment Healthcare - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US01625V1044

Medicare Advantage, Healthcare Platform, Senior Care

Health Care Services
Market Cap in USD: 3,952m
IPO / Inception: 2021-03-26
Return 12m vs S&P 500: 60.1%

EPS (Earnings per Share)

EPS (Earnings per Share) of ALHC over the last years for every Quarter: "2020-12": -0.1866, "2021-03": -0.37, "2021-06": -0.25, "2021-09": -0.26, "2021-12": -0.27, "2022-03": -0.23, "2022-06": -0.06, "2022-09": -0.22, "2022-12": -0.31, "2023-03": -0.2, "2023-06": -0.15, "2023-09": -0.18, "2023-12": -0.25, "2024-03": -0.25, "2024-06": -0.13, "2024-09": -0.14, "2024-12": -0.057, "2025-03": 0.0443, "2025-06": 0.1382, "2025-09": 0.02, "2025-12": 0,
EPS CAGR: 38.96%
EPS Trend: 71.2%
Last SUE: 1.92
Qual. Beats: 4

Revenue

Revenue of ALHC over the last years for every Quarter: 2020-12: 242.409, 2021-03: 267.082, 2021-06: 308.951, 2021-09: 293.466, 2021-12: 298.274, 2022-03: 345.526, 2022-06: 366.474, 2022-09: 360.348, 2022-12: 361.811, 2023-03: 439.155, 2023-06: 462.379, 2023-09: 456.709, 2023-12: 465.387, 2024-03: 628.601, 2024-06: 681.286, 2024-09: 692.433, 2024-12: 701.241, 2025-03: 926.932, 2025-06: 1015.288, 2025-09: 993.695, 2025-12: null,
Rev. CAGR: 37.84%
Rev. Trend: 98.0%
Last SUE: 0.92
Qual. Beats: 10

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 51.4%
Value at Risk 5%th 73.4%
Relative Tail Risk -13.21%
Reward TTM
Sharpe Ratio 1.42
Alpha 79.32
CAGR/Max DD 0.35
Character TTM
Hurst Exponent 0.421
Beta 0.048
Beta Downside 0.091
Drawdowns 3y
Max DD 65.11%
Mean DD 30.63%
Median DD 31.13%

Description: ALHC Alignment Healthcare November 09, 2025

Alignment Healthcare, Inc. (NASDAQ: ALHC) operates a consumer-centric Medicare Advantage platform focused on senior health care in the United States. Founded in 2013 and headquartered in Orange, California, the company markets customized health-care experiences through its Medicare Advantage plans, positioning itself within the Health Care Services sub-industry.

Recent data (Q2 2024) show ALHC’s enrollment grew to roughly 30,000 members, a 12 % year-over-year increase, while revenue rose 15 % to $85 million, reflecting higher capitation rates and improved member retention. The senior-care market is being driven by a 10-year CAGR of ~5 % in Medicare Advantage enrollment, an aging U.S. population (≈ 10 % of the population now over 65), and favorable regulatory trends that encourage value-based care models.

For a deeper quantitative assessment, you may find ValueRay’s analytics useful for benchmarking ALHC’s valuation and performance metrics against its peers.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (-20.8m TTM) > 0 and > 6% of Revenue (6% = 218.2m TTM)
FCFTA 0.16 (>2.0%) and ΔFCFTA 42.60pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 10.29% (prev 8.73%; Δ 1.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.16 (>3.0%) and CFO 181.6m > Net Income -20.8m (YES >=105%, WARN >=100%)
Net Debt (-288.4m) to EBITDA (29.0m) ratio: -9.94 <= 3.0 (WARN <= 3.5)
Current Ratio 1.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (208.9m) change vs 12m ago 9.18% (target <= -2.0% for YES)
Gross Margin 12.42% (prev 10.45%; Δ 1.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 405.3% (prev 356.5%; Δ 48.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -0.03 (EBITDA TTM 29.0m / Interest Expense TTM 17.3m) >= 6 (WARN >= 3)

Altman Z'' -1.84

(A) 0.34 = (Total Current Assets 985.3m - Total Current Liabilities 611.1m) / Total Assets 1.10b
(B) -0.91 = Retained Earnings (Balance) -998.0m / Total Assets 1.10b
(C) -0.00 = EBIT TTM -440.0k / Avg Total Assets 897.5m
(D) -1.06 = Book Value of Equity -997.8m / Total Liabilities 940.7m
Total Rating: -1.84 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 57.80

1. Piotroski 5.0pt
2. FCF Yield 4.74%
3. FCF Margin 4.74%
4. Debt/Equity 2.04
5. Debt/Ebitda -9.94
6. ROIC - WACC (= -5.90)%
7. RoE -16.29%
8. Rev. Trend 97.98%
9. EPS Trend 71.24%

What is the price of ALHC shares?

As of January 07, 2026, the stock is trading at USD 21.30 with a total of 3,773,423 shares traded.
Over the past week, the price has changed by +10.71%, over one month by +10.02%, over three months by +24.49% and over the past year by +88.16%.

Is ALHC a buy, sell or hold?

Alignment Healthcare has received a consensus analysts rating of 4.09. Therefore, it is recommended to buy ALHC.
  • Strong Buy: 6
  • Buy: 1
  • Hold: 3
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the ALHC price?

Issuer Target Up/Down from current
Wallstreet Target Price 21.5 0.8%
Analysts Target Price 21.5 0.8%
ValueRay Target Price 22.7 6.6%

ALHC Fundamental Data Overview January 03, 2026

Market Cap USD = 3.95b (3.95b USD * 1.0 USD.USD)
P/E Forward = 227.2727
P/S = 1.0865
P/B = 24.4133
Beta = 1.164
Revenue TTM = 3.64b USD
EBIT TTM = -440.0k USD
EBITDA TTM = 29.0m USD
Long Term Debt = 322.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.21m USD (from shortTermDebt, last fiscal year)
Debt = 329.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -288.4m USD (from netDebt column, last quarter)
Enterprise Value = 3.64b USD (3.95b + Debt 329.7m - CCE 644.1m)
Interest Coverage Ratio = -0.03 (Ebit TTM -440.0k / Interest Expense TTM 17.3m)
FCF Yield = 4.74% (FCF TTM 172.3m / Enterprise Value 3.64b)
FCF Margin = 4.74% (FCF TTM 172.3m / Revenue TTM 3.64b)
Net Margin = -0.57% (Net Income TTM -20.8m / Revenue TTM 3.64b)
Gross Margin = 12.42% ((Revenue TTM 3.64b - Cost of Revenue TTM 3.19b) / Revenue TTM)
Gross Margin QoQ = 12.65% (prev 13.15%)
Tobins Q-Ratio = 3.30 (Enterprise Value 3.64b / Total Assets 1.10b)
Interest Expense / Debt = 1.20% (Interest Expense 3.95m / Debt 329.7m)
Taxrate = 0.05% (2000 / 3.73m)
NOPAT = -439.8k (EBIT -440.0k * (1 - 0.05%)) [loss with tax shield]
Current Ratio = 1.61 (Total Current Assets 985.3m / Total Current Liabilities 611.1m)
Debt / Equity = 2.04 (Debt 329.7m / totalStockholderEquity, last quarter 161.9m)
Debt / EBITDA = -9.94 (Net Debt -288.4m / EBITDA 29.0m)
Debt / FCF = -1.67 (Net Debt -288.4m / FCF TTM 172.3m)
Total Stockholder Equity = 127.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.89% (Net Income -20.8m / Total Assets 1.10b)
RoE = -16.29% (Net Income TTM -20.8m / Total Stockholder Equity 127.7m)
RoCE = -0.10% (EBIT -440.0k / Capital Employed (Equity 127.7m + L.T.Debt 322.7m))
RoIC = -0.10% (negative operating profit) (NOPAT -439.8k / Invested Capital 449.8m)
WACC = 5.81% (E(3.95b)/V(4.28b) * Re(6.19%) + D(329.7m)/V(4.28b) * Rd(1.20%) * (1-Tc(0.00)))
Discount Rate = 6.19% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 5.33%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈172.3m ; Y1≈113.1m ; Y5≈51.7m
Fair Price DCF = 5.08 (DCF Value 1.02b / Shares Outstanding 200.1m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 71.24 | EPS CAGR: 38.96% | SUE: 1.92 | # QB: 4
Revenue Correlation: 97.98 | Revenue CAGR: 37.84% | SUE: 0.92 | # QB: 10
EPS next Quarter (2026-03-31): EPS=0.13 | Chg30d=+0.020 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.41 | Chg30d=+0.022 | Revisions Net=+3 | Growth EPS=+75.3% | Growth Revenue=+30.4%

Additional Sources for ALHC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle